Growth Investment Partners (GIP) Ghana, an investment platform established by British International Investment (BII), has made a strategic investment in mPharma Ghana, one of Africa’s leading health-technology companies, to support its regional expansion and strengthen access to affordable, quality medicines.
The investment will accelerate mPharma’s growth plans, with a strong focus on expanding into Francophone West Africa, particularly Togo and Benin, while improving inventory efficiency and operational performance across its existing pharmacy network.
mPharma’s leadership says the partnership with GIP Ghana comes at a critical time, as African countries grapple with rising healthcare demand, growing populations, and persistent gaps in access to treatment.
“Access to affordable medicines remains one of Africa’s most pressing healthcare challenges. With GIP’s support, we can scale our partnerships with pharmacies and healthcare providers to ensure equitable access to quality care across Ghana and Francophone West Africa,” said Kwesi Arhin, Chief Executive of mPharma.
Scaling a Proven Model for Medicine Access
Founded in 2013, mPharma has built a reputation as a pioneer in addressing one of Africa’s most persistent healthcare challenges: the affordability and availability of essential medicines.
The company operates an asset-light franchise model under its Mutti and QualityRx brands, allowing independent pharmacies to join its network while retaining ownership.
Through proprietary software and data analytics, mPharma helps partner pharmacies optimise inventory, reduce stock-outs and expiries, standardise pricing, and improve supply chain efficiency.
This model lowers operating costs, improves medicine availability, and ensures patients can access reliable, fairly priced drugs, particularly in underserved communities where public health infrastructure is often stretched.
Targeting Francophone West Africa
The expansion into Togo and Benin marks an important strategic step for mPharma, extending its footprint beyond Anglophone markets and into regions where fragmented supply chains, high medicine prices, and inconsistent quality remain significant barriers to care.
By partnering with local pharmacies and distributors, mPharma aims to strengthen pharmaceutical ecosystems while adapting its model to local regulatory and market conditions.
For GIP Ghana, the investment aligns with its mandate to back commercially sustainable businesses that deliver essential services and social impact.
“Our goal is to back enterprises that improve essential services for ordinary people. This expansion will help communities gain better access to quality medicines while strengthening the resilience of local health systems,” said Jacob Kholi, Chief Executive and Investment Officer at GIP Ghana.
Private Capital and Public Health Goals Converge
The deal reflects a broader trend of development finance institutions and impact-oriented investors using private capital to strengthen healthcare delivery across Africa, particularly where public systems face funding and capacity constraints.
By combining technology, partnerships, and scalable business models, companies like mPharma are increasingly seen as critical complements to government health systems, improving efficiency, lowering costs, and expanding reach.
As mPharma pushes into new markets and deepens its regional presence, the investment from GIP Ghana positions the company to play a larger role in shaping how medicines are distributed and accessed across West Africa.
Talking Points
It is encouraging that GIP Ghana is backing a health-tech company that directly addresses one of Africa’s most persistent challenges: access to affordable, quality medicines.
This investment positions mPharma not just as a commercial pharmacy platform, but as critical infrastructure for strengthening medicine supply chains across West Africa.
At Techparley, we see this as an example of how patient capital can be deployed to build resilient systems in sectors where the social impact is as important as the financial return.
mPharma’s asset-light franchise model allows independent pharmacies to improve efficiency, pricing, and reliability without losing ownership, which makes the model more scalable and locally grounded.
As mPharma scales, partnerships with governments, health insurers, NGOs, and pharmaceutical manufacturers could accelerate adoption and embed the platform more deeply into national health systems.
With the right strategic support, mPharma has the potential to become a cornerstone of pharmaceutical access in West Africa, helping to shift healthcare delivery from fragmented supply chains to integrated, reliable networks.
——————-
Bookmark Techparley.com for the most insightful technology news from the African continent.
Follow us on Twitter @Techparleynews, on Facebook at Techparley Africa, on LinkedIn at Techparley Africa, or on Instagram at Techparleynews.
